TNF-a Inhibition and the Treatment of Hidradenitis Suppurativa: Clinical Pearls

Share

Bruce Strober, MD, PhD

What’s new with the treatment of hidradenitis suppurativa and TNF-a inhibition? Dr Strober provides us with his clinical pearls…

  • Both adalimumab and infliximab effectively treat many features of hidradenitis suppurativa.
  • Adalimumab has been evaluated in the most rigorous studies ever conducted on a potential treatment for hidradenitis suppurativa.
  • Adalimumab requires weekly dosing at 40 mg to be consistently effective.
  • TNF-a levels are elevated in lesional and perilesional skin from patients with hidradenitis suppurativa.
  • TNF-a inhibitors such as adalimumab and infliximab reduce not only lesion counts but also pain.
  • AbbVie will seek FDA-approval for the treatment of hidradenitis suppurativa with adalimumab.
  • Etanercept is not effective for the treatment of hidradenitis suppurativa.